Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode.Episode 15 Drop: Atopic Dermatitis Breakthrough: Precision Treatment and the Promise of AdvanceAD-Tx™In this episode of Skinfluenced: The Skin Podcast, we explore a groundbreaking advancement in the management of moderate-to-severe atopic dermatitis (AD). Castle Biosciences’ new AdvanceAD-Tx™ test, launched THIS MONTH, introduces precision medicine to dermatology with a 487-gene expression profile (GEP) that decodes each patient’s unique immune biology. By classifying results into different profile groups, clinicians can now identify which patients are more likely to respond to specific systemic therapies—before treatment even begins.We're breaking down:The IDENTITY study which showed how patients can now get EASI-90 nearly 4X fasterHow this innovation could transform treatment selection, improve patient outcomes, and redefine the role of molecular testing in dermatology.⚠️ Educational purposes only. Not medical advice.Link to Source(s):Castle Biosciences, Inc. Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis. Accessed November 11, 2025. https://ir.castlebiosciences.com/news/news-details/2025/Castle-Biosciences-Launches-AdvanceAD-Tx-to-Help-Guide-Systemic-Treatment-Decision-Making-in-Patients-with-Moderate-to-Severe-Atopic-Dermatitis/default.aspxCastle Biosciences, Inc. Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis. News Release. November 3, 2025.Chiesa Fuxench, Zelma C., et al. Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population. Journal of Investigative Dermatology. 2019; 139: 583–590.Silverberg, Jonathan I., et al. Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. Annals of Allergy, Asthma & Immunology. 2018; 121(3): 340-347.Silverberg, Jonathan I., et al. The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective, multi-center trial. Castle Biosciences AdvanceAD-Tx™ Launch Slide Deck. November 2025.The Derm Digest. Castle Biosciences Rolls Out AdvanceAD-Tx. Accessed November 11, 2025. https://thedermdigest.com/castle-biosciences-rolls-out-advancead-tx/?utm_source=Klaviyo&utm_medium=campaign&_kx=LStbfMDiK_dFORiyt1p_kkItQ6IXDv9wQWWp60o95yV8qS2-9Wbebg-OUZpTxSvC.TYhhHR

Ver todos los episodios